Open access
Open access
Powered by Google Translator Translator

Pediatrics – Rheumatology

Podcast | Childhood-Onset SLE

6 Apr, 2023 | 13:12h | UTC

#77: Childhood-Onset SLE – Is It Sometimes Lupus? – The Cribsiders

 


RCT | Hydroxychloroquine in children with proliferative lupus nephritis

30 Mar, 2023 | 14:11h | UTC

Hydroxychloroquine in children with proliferative lupus nephritis: a randomized clinical trial – European Journal of Pediatrics

 


RCT | Genicular nerve block vs. intra-articular triamcinolone in juvenile idiopathic arthritis

10 Feb, 2023 | 13:36h | UTC

Genicular nerve block in juvenile idiopathic arthritis: a randomized clinical trial – Clinical Rheumatology

 


RCT | Methylprednisolone vs. immunoglobulins equally effective in PIMS temporally associated with SARS-CoV-2

8 Feb, 2023 | 12:42h | UTC

Methylprednisolone versus intravenous immunoglobulins in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): an open-label, multicentre, randomised trial – The Lancet Child & Adolescent Health

 


SR | Intravenous immunoglobulin for the treatment of Kawasaki disease

7 Feb, 2023 | 13:58h | UTC

Intravenous immunoglobulin for the treatment of Kawasaki disease – Cochrane Library

Summary: Immunoglobulin treatment for Kawasaki disease – Cochrane Library

Related:

Analysis of Coronary Arterial Aneurysm Regression in Patients With Kawasaki Disease by Aneurysm Severity: Factors Associated With Regression – Journal of the American Heart Association

Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan – JAMA Network Open

Systematic Review: Corticosteroids for the treatment of Kawasaki disease in children.

Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease

Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives – Frontiers in Medicine

 


Cohort Study | Analysis of factors associated with coronary arterial aneurysm regression in patients with Kawasaki disease

7 Feb, 2023 | 13:56h | UTC

Analysis of Coronary Arterial Aneurysm Regression in Patients With Kawasaki Disease by Aneurysm Severity: Factors Associated With Regression – Journal of the American Heart Association

Related:

Intravenous immunoglobulin for the treatment of Kawasaki disease – Cochrane Library

Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan – JAMA Network Open

Systematic Review: Corticosteroids for the treatment of Kawasaki disease in children.

Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease

Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives – Frontiers in Medicine

 


2ry analysis of a RCT | Vitamin D supplementation did not influence growth, body composition, and pubertal development in children.

30 Nov, 2022 | 13:49h | UTC

Influence of Vitamin D Supplementation on Growth, Body Composition, and Pubertal Development Among School-aged Children in an Area With a High Prevalence of Vitamin D Deficiency: A Randomized Clinical Trial – JAMA Pediatrics (free for a limited period)

Commentary: Vitamin D Supplementation Does Not Influence Growth in Children – HealthDay

 


Recommendations for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis.

3 Nov, 2022 | 14:01h | UTC

Canadian Rheumatology Association Recommendations for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-associated Uveitis – The Journal of Rheumatology

 


RCT | Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis.

15 Aug, 2022 | 12:05h | UTC

Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial – Annals of Rheumatic Diseases

 


EULAR/PRES recommendations for vaccination of pediatric patients with autoimmune inflammatory rheumatic diseases.

24 Jun, 2022 | 11:17h | UTC

EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021 – Annals of Rheumatic Diseases

 


EULAR/ACR points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases.

24 Jun, 2022 | 11:23h | UTC

The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist – Annals of Rheumatic Diseases

 


Consensus Paper: Diagnosis and treat-to-target management of macrophage activation syndrome in children.

24 Jun, 2022 | 11:13h | UTC

Egyptian evidence-based consensus on clinical practice guidelines for the diagnosis and treat-to-target management of macrophage activation syndrome in children – Egyptian Rheumatology and Rehabilitation

 


Cohort Study: Association of maternal autoimmune diseases with risk of mental disorders in offspring in Denmark.

20 Apr, 2022 | 09:19h | UTC

Association of Maternal Autoimmune Diseases With Risk of Mental Disorders in Offspring in Denmark – JAMA Network Open

 

Commentary on Twitter

https://twitter.com/JAMANetworkOpen/status/1515057370715594753

 


RCT: Long-term efficacy and safety of up to 108 weeks of Ixekizumab in pediatric patients with moderate to severe plaque psoriasis.

18 Apr, 2022 | 09:49h | UTC

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial – JAMA Dermatology

Original Study: Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS) – British Journal of Dermatology

 

Commentary on Twitter

 


Cohort Study: Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection.

12 Apr, 2022 | 09:57h | UTC

Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study – Canadian Medical Association Journal

News Release: Children older than 5 at higher risk of COVID-19-related multisystem inflammatory syndrome – Canadian Medical Association Journal

Commentary: Older Kids More Vulnerable to MIS-C: Study – HealthDay

 


Acute phase of Kawasaki disease: a review of national guideline recommendations.

12 Apr, 2022 | 08:32h | UTC

Acute phase of Kawasaki disease: a review of national guideline recommendations – European Journal of Pediatrics

 


Systematic Review: Epidemiology of musculoskeletal manifestations in pediatric inflammatory bowel disease.

7 Apr, 2022 | 07:55h | UTC

Epidemiology of Musculoskeletal Manifestations in Pediatric Inflammatory Bowel Disease: A Systematic Review – ACR Open Rheumatology

 


BSR guideline on management of pediatric, adolescent and adult patients with idiopathic inflammatory myopathy.

4 Apr, 2022 | 01:05h | UTC

British Society for Rheumatology guideline on management of paediatric, adolescent and adult patients with idiopathic inflammatory myopathy – Rheumatology

 


Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.

1 Apr, 2022 | 08:45h | UTC

Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials – eBioMedicine

Commentary: Network meta-analysis rates treatments for Kawasaki disease – medwire News

 


Guideline: Treatment of unspecific back pain in children and adolescents.

29 Mar, 2022 | 09:52h | UTC

Treatment of Unspecific Back Pain in Children and Adolescents: Results of an Evidence-Based Interdisciplinary Guideline – Children

 


ACR/Vasculitis Foundation Guideline for the management of Kawasaki Disease.

9 Mar, 2022 | 10:01h | UTC

2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Kawasaki Disease

 


ACR Guidelines for the Treatment of Juvenile Idiopathic Arthritis.

4 Mar, 2022 | 08:58h | UTC

News Release: The American College of Rheumatology releases two updated guidelines for treatment of juvenile idiopathic arthritis – American College of Rheumatology

 

2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging – Arthritis & Rheumatology

 

2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

 


What’s New in Pediatric Orthopedics.

25 Feb, 2022 | 10:48h | UTC

What’s New in Pediatric Orthopaedics – The Journal of Bone & Joint Surgery

 


Anti-inflammatory treatment of Kawasaki Disease: comparison of current guidelines and perspectives.

25 Feb, 2022 | 10:29h | UTC

Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives – Frontiers in Medicine

 


Review: Juvenile idiopathic arthritis.

28 Jan, 2022 | 08:13h | UTC

Juvenile idiopathic arthritis – Nature Reviews Disease Primers (if the link is paywalled, try this one)

Infographic: Juvenile idiopathic arthritis (if the link is paywalled, try this one)

 

Commentary on Twitter

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts US$ 7.00/month

No spam, just news.